CD274 and cancer: Most of these studies (94 papers) focused on anti-PD1/PDL1 antibodies without local treatment for advanced, metastatic, or recurrent cancers, while the remaining six studies evaluated anti-PD1/PDL1 antibodies as an adjuvant treatment before or after radical resection or chemoradiotherapy for cancers.